CA3063285A1 - Preparation of biologically active complexes - Google Patents

Preparation of biologically active complexes Download PDF

Info

Publication number
CA3063285A1
CA3063285A1 CA3063285A CA3063285A CA3063285A1 CA 3063285 A1 CA3063285 A1 CA 3063285A1 CA 3063285 A CA3063285 A CA 3063285A CA 3063285 A CA3063285 A CA 3063285A CA 3063285 A1 CA3063285 A1 CA 3063285A1
Authority
CA
Canada
Prior art keywords
seq
biologically active
peptide
salt
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3063285A
Other languages
English (en)
French (fr)
Inventor
Aftab NADEEM
Catharina Svanborg
Chin Shing HO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hamlet Pharma AB
Original Assignee
Hamlet Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hamlet Pharma AB filed Critical Hamlet Pharma AB
Publication of CA3063285A1 publication Critical patent/CA3063285A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Inorganic Chemistry (AREA)
CA3063285A 2017-05-14 2018-05-14 Preparation of biologically active complexes Pending CA3063285A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1707715.7 2017-05-14
GBGB1707715.7A GB201707715D0 (en) 2017-05-14 2017-05-14 Preperation of biologically active complexes
PCT/EP2018/062396 WO2018210759A1 (en) 2017-05-14 2018-05-14 Preparation of biologically active complexes

Publications (1)

Publication Number Publication Date
CA3063285A1 true CA3063285A1 (en) 2018-11-22

Family

ID=59201543

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3063285A Pending CA3063285A1 (en) 2017-05-14 2018-05-14 Preparation of biologically active complexes

Country Status (13)

Country Link
US (3) US20200140481A1 (OSRAM)
EP (2) EP3811967B1 (OSRAM)
JP (2) JP7672122B2 (OSRAM)
KR (2) KR20260021814A (OSRAM)
CN (2) CN119700935A (OSRAM)
AU (1) AU2018269304B2 (OSRAM)
CA (1) CA3063285A1 (OSRAM)
DK (2) DK3618848T3 (OSRAM)
ES (2) ES2861252T3 (OSRAM)
FI (1) FI3811967T3 (OSRAM)
GB (1) GB201707715D0 (OSRAM)
PL (2) PL3618848T3 (OSRAM)
WO (1) WO2018210759A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201621752D0 (en) * 2016-12-20 2017-02-01 Hamlet Pharma Ab Therapeutically active complexes
GB201707715D0 (en) * 2017-05-14 2017-06-28 Hamlet Pharma Ab Preperation of biologically active complexes
WO2019243547A1 (en) * 2018-06-20 2019-12-26 Hamlet Pharma Ab Therapeutically active complexes
GB2574845A (en) * 2018-06-20 2019-12-25 Hamlet Pharma Ab Therapeutically active complexes
WO2021032807A1 (en) * 2019-08-20 2021-02-25 Hamlet Pharma Ab Combination of a chemotherapeutic agent and alpha-lactoglubulin-oleic acid complex for cancer therapy
GB202015836D0 (en) * 2020-10-06 2020-11-18 Hamlet Pharma Ab Compositions
CN120239612A (zh) 2022-10-03 2025-07-01 林南制药公司 一种用于治疗或预防癌症的包含α-乳清蛋白和脂肪酸或脂质的复合物
GB202303177D0 (en) 2023-03-03 2023-04-19 Linnane Pharma Ab Method of predicting response to treatment
WO2025186107A1 (en) 2024-03-04 2025-09-12 Linnane Pharma Ab Therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550263B2 (en) * 2003-09-05 2009-06-23 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
US8796218B2 (en) 2009-01-09 2014-08-05 Hamlet Pharma Ab Complex and production process
WO2010131237A1 (en) 2009-05-13 2010-11-18 Agriculture And Food Development Authority (Teagasc) A process for producing a biologically active globular protein complex
GB0908279D0 (en) 2009-05-14 2009-06-24 Enovate Systems Ltd Subsea winch
EP2643010B1 (en) 2010-11-24 2016-11-16 HAMLET Pharma AB Biologically active complex and its preparation
HUE038910T2 (hu) * 2012-08-09 2018-12-28 Hamlet Pharma Ab Profilaktikus és gyógytáp terápia
GB201621752D0 (en) * 2016-12-20 2017-02-01 Hamlet Pharma Ab Therapeutically active complexes
GB201707715D0 (en) 2017-05-14 2017-06-28 Hamlet Pharma Ab Preperation of biologically active complexes

Also Published As

Publication number Publication date
DK3811967T5 (da) 2024-08-19
JP7672122B2 (ja) 2025-05-07
JP2023075290A (ja) 2023-05-30
DK3618848T3 (da) 2021-03-01
EP3811967B1 (en) 2023-12-20
JP7705160B2 (ja) 2025-07-09
ES2973290T3 (es) 2024-06-19
PL3618848T3 (pl) 2021-06-14
AU2018269304A1 (en) 2019-11-21
WO2018210759A1 (en) 2018-11-22
PL3811967T3 (pl) 2024-03-18
KR20260021814A (ko) 2026-02-13
JP2020519673A (ja) 2020-07-02
EP3618848A1 (en) 2020-03-11
KR20200015557A (ko) 2020-02-12
CN110650746B (zh) 2024-12-31
ES2861252T3 (es) 2021-10-06
US12331073B2 (en) 2025-06-17
EP3811967A1 (en) 2021-04-28
AU2018269304B2 (en) 2025-02-27
GB201707715D0 (en) 2017-06-28
US20260085088A1 (en) 2026-03-26
US20210130394A1 (en) 2021-05-06
FI3811967T3 (fi) 2023-12-28
EP3618848B1 (en) 2020-11-25
CN119700935A (zh) 2025-03-28
CN110650746A (zh) 2020-01-03
US20200140481A1 (en) 2020-05-07
DK3811967T3 (da) 2024-01-08

Similar Documents

Publication Publication Date Title
US12331073B2 (en) Preparation of biologically active complexes
Luan et al. Cytotoxic and antitumor peptides as novel chemotherapeutics
US9415114B2 (en) Conformations of divergent peptides with mineral binding affinity
US20230372450A1 (en) Method for preparing a composition comprising an unfolded protein
CN102205114A (zh) 促红细胞生成素来源肽在制备治疗神经系统自身免疫性疾病的药物中的应用
CN105524139A (zh) 高活性的肿瘤抑制剂及其制法和应用
HK40050699A (en) Preparation of biologically active complexes
HK40050699B (en) Preparation of biologically active complexes
CN115515619A (zh) 抗癌蛋白
HK40025666A (en) Biologically active complexes and therapeutic uses thereof
HK40025666B (en) Biologically active complexes and therapeutic uses thereof
TWI825397B (zh) 包含il-2蛋白及cd80蛋白的融合蛋白調配物
KR102532557B1 (ko) Dsg2 유래 펩타이드
JP2012529423A5 (OSRAM)
JP2022545429A (ja) がん治療のための化学療法剤とα－ラクトグロブリン－オレイン酸複合体との組合せ
CN116157142A (zh) 肽、肽的盐、药物组合物和生物体组织钙化抑制剂
GB2574845A (en) Therapeutically active complexes
JP2023540800A (ja) リフォールディングされたヒト血清アルブミン及びその抗腫瘍ための使用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230510

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240903

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250121

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250506

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250506

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250509

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250509